HHS grants enforcement discretion on six compounded peptides pending Bulks List
HHS said on October 28, 2026 it will not enforce against pharmacies, federal facilities and physicians compounding six peptides while FDA works on its Bulks List rulemaking.
On October 28, 2026, the U.S. Department of Health and Human Services issued an interim policy stating it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound a specified set of six peptides, while FDA proceeds with rulemaking on the compounding "Bulks List" under the federal drug compounding framework. The excerpt does not identify the six peptides or the precise conditions attached to the non-enforcement stance, so the scope of the safe harbor should be confirmed against the full policy text and any accompanying guidance.
Why sophisticated counsel should care: compounding enforcement posture is a recurring source of risk for telehealth and anti-aging peptide providers, 503A and 503B outsourcing facilities, and hospitals or clinics that prepare sterile and nonsterile preparations. An interim enforcement carve-out can effectively legitimize product lines that remain legally unsettled, while also creating compliance and truthful-marketing exposure where a given product falls outside the carve-out.
Concrete next steps: map each client peptide to the interim policy's conditions; audit labeling and marketing claims for indications the non-enforcement policy does not cover; and track FDA's Bulks List rulemaking docket, since the interim posture is expressly framed as temporary and may end with different bulk-substance determinations for peptides.